Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk - Lesniak, Robert K.; Nichols, R. Jeremy; Montine, Thomas J. (Frontiers in Neurology, 2022)